期刊文献+

A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor 被引量:1

A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor
下载PDF
导出
摘要 AIM: To develop a novel process for production of HAV in Vero cells grown on microcarriers in a bioreactor.METHODS: Vero cells infected with HAV strain W were seeded at an initial density of 1×10^5 cells/mL into a 7-L bioreactor containing Cytodex-I microcarriers. During the stage of cell proliferation, the following conditions were applied: pH 7.2±0.2, temperature 37±0.2℃, dissolved oxygen 40% of air saturation and agitation rate 40 r/min.After the stage of virus culture started, the culture conditions were altered to pH 7.2±0.2, temperature 35±0.2℃,dissolved oxygen 25% of air saturation, agitation rate 50 r/min and perfusion of fresh medium at a flux of 20 mL/h. During the course of fermentation, cell density, HAV antigen titre,glucose, lactate and ammonia levels were monitored. A control experiment using conventional static culture was conducted in the T150 flask.RESULTS: After a 28-d cultivation, cell density increased to 14.0×10^5 cells/mL in the bioreactor, 5.6×10^9 viable cells and 4 000 mL virus suspension with a titre of 1:64 were harvested.The viral antigen output per cell unit in the bioreactor was 3-fold higher than that in the T150 flask. Meanwhile the metabolic mode of Vero cells did not change after the infection with HAY strain W.CONCLUSION: The process for production of HAV in Vero cells grown on microcarriers in a bioreactor is a novel,efficient and practical way to obtain virus antigen for vaccine purpose. This approach produces more cells and HAV antigen than the conventional static culture. With futher improvement, it is possible to be used for the production of hepatitis A vaccine.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第17期2571-2573,共3页 世界胃肠病学杂志(英文版)
基金 Supported by the Natural Science Foundation of Yunnan Province,No.1999C0023Q
  • 相关文献

参考文献4

二级参考文献11

  • 1[1]Neermann J, Wagner R. Comparative analysis of glucose and glutamine metabolism in transformed mammalian cell lines,insect and primary liver cell.J Cell Physiol, 1996,166:152- 169.
  • 2[2]Petch D,Butler M A.Profile of energy metabolism in a murine bybridoma:Glucose and glutamine utilization. J Cell Physiol, 1994, 161:71 -76.
  • 3[3]Liunggren J, haggstrom L. Catabolic contral of hybridoma cells by glucose and glutamine limited fed - batch culture. Biotechnol Bioeng, 1994,44:808-818.
  • 4[4]Dovevskog M, Ljunggren J, Ohman L. Physiology of cultured animal cells. J Biotechnol, 1997,59:103 - 115.
  • 5[5]Sauer P W, Burky J E, Wesson M C, et a1. A high - yielding, generic fed-batch cell culture process for production of recombinant antibodies.Bioeng,2000,67: 585 - 597.
  • 6徐志一,中华预防医学杂志,1996年,30卷,增刊,3页
  • 7胡善联,流行病学.2(第2版),1996年,21页
  • 8Daniel G,Emmanuel V,Martine W,et al.Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults[].Vaccine.1995
  • 9Christian G,Jane Z,Michael L,et al.Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study[].Journal of Medical Virology.1995
  • 10Olga Castillo de Febres.The investigation on the savety immunogen:Antibody maitenace to apply HAV inactived vaccine in aged 4-15 years chidren[].Vaccine.1999

共引文献31

同被引文献12

  • 1Samia Rourou,Arno Ark,Samy Majoul,Khaled Trabelsi,Tiny Velden,Héla Kallel.A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor[J],2009.
  • 2Schuller E,Jilma B,Voicu V,et al.Long-term immunogenicityof the new Vero cell-derived,inactivated Japanese encephalitis vi-rus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 studyVaccine,2008.
  • 3Toriniwa H,Komiya T.Japanese encephalitis virus production inVero cells with serum-free medium using a novel oscillating biore-actorBiologicals,2007.
  • 4Kennedy RB,Ovsyannikova I,Jacobson RM,et al.The immu-nology of smallpox vaccinesCurrent Opinion in Immunolo-gy,2009.
  • 5Kennedy RB,Ovsyannikova I,Poland GA.Smallpox vaccines forbiodefenseVaccine,2009.
  • 6Liu CC,Lee SC,Butler M,et al.High genetic stability of Den-gue virus propagated in MRC-5 cells as compared to the viruspropagated in Vero cellsPLoS ONE,2008.
  • 7LiuCC,Lian WC,Butler M,et al.High immunogenic enterovir-us 71 strain and its production using serum-free microcarrier Verocell cultureVaccine,2007.
  • 8Minor P.Vaccine-derived poliovirus (VDPV):Impact on polio-myelitis eradicationVaccine,2009.
  • 9Tiwari M,Parida M,Santhosh SR,et al.Assessment of immu-nogenic potential of Vero adapted formalin inactivated vaccine de-rived from novel ECSA genotype of Chikungunya virusVaccine,2009.
  • 10Qin E,Shi H,Tang L,et al.Immunogenicity and protective ef-ficacy in monkeys of purified inactivated Vero-cell SARS vaccineVaccine,2006.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部